Key result
Selective IKACh blockers, such as NIP-151, effectively terminated atrial fibrillation and prolonged the atrial effective refractory period without affecting ventricular repolarization in animal models.
Selective acetylcholine-sensitive K+-channel (IKACh) blockade represents a promising atrium-selective therapeutic strategy for atrial fibrillation that may avoid the ventricular proarrhythmic side effects of traditional antiarrhythmic drugs.
Supports atrium-selective IKACh blockade for AF; leaves open translation to human trials.
No takes yet. Share an insight, caveat, or question.
Norio Hashimoto (2010) conducted a review in Atrial fibrillation. Selective acetylcholine-sensitive K+ channel (IKACh) blockers (e.g., NIP-151, tertiapin) vs. Vehicle or Class III antiarrhythmic drugs (e.g., dofetilide) was evaluated on Termination of atrial fibrillation and prolongation of atrial effective refractory period in animal models. Selective IKACh blockers, such as NIP-151, effectively terminated atrial fibrillation and prolonged the atrial effective refractory period without affecting ventricular repolarization in animal models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: